Issue Date: May 15, 2017
DSM and Amyris pursue vitamin A
DSM will invest $25 million in the biobased chemicals maker Amyris and may follow with another $25 million. At the same time, the two firms will work on health-related products. They have an exclusive agreement to develop a fermentation route to vitamin A, which is normally made via chemical synthesis. If DSM does invest the full $50 million, it will own almost one-quarter of Amyris. Other, unnamed investors have committed an additional $45 million. Amyris . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society